Posted on May 18, 2019 by Sitemaster
We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab. Keytruda, HSPC, mCRPC, nivolumab, Opdivo, PD-1, PD-L1, pembrolizumab, Tecentriq | 7 Comments »
Posted on December 10, 2018 by Sitemaster
We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, efficacy, Keytruda, outcome, pembrolizumab, safety, trial | 5 Comments »
Posted on September 5, 2018 by Sitemaster
A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: defect, immunotherapy, mismatch, nivolumab, PD-1, pembrolizumab, repair | Leave a comment »
Posted on May 24, 2017 by Sitemaster
Yesterday, the US Food & Drug Administration (FDA) did something it has never done before. It approved a drug for the treatment of a type of cancer based exclusively on the presence of a specific biomarker — with no reference to the location of the cancer in the patient’s body. … READ MORE …
Filed under: Drugs in development | Tagged: approval, biomarker, FDA, pembrolizumab | 8 Comments »
Posted on November 6, 2014 by Sitemaster
Late yesterday, Advaxis Immunotherapies announced the potential initiation of human trials of another new form of immunotherapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADXS31-142, castration-resistant, immunotherapy, mCRPC, metastatic, pembrolizumab | Leave a comment »
Posted on August 25, 2014 by Sitemaster
A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADXS-PSA, castration-resistant, immunotherapy, mCRPC, metastatic, PD-1, pembrolizumab | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 